Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
Lexaria Bioscience (NASDAQ:LEXX) positions its DehydraTECH technology as a potential solution for the GLP-1 industry's biggest challenge: adverse effects. The GLP-1 market is experiencing remarkable growth, with projected revenues increasing from $53.5 billion in 2024 to $70.1 billion in 2025, and expected to reach $156 billion by 2030.
However, 47-64% of GLP-1 users discontinue treatment within 1-2 years, primarily due to gastrointestinal side effects. Notably, 75.7% of patients experience gastrointestinal adverse events with leading GLP-1 drugs. Lexaria's DehydraTECH technology has demonstrated in human clinical testing its ability to reduce side effects in the top three GLP-1 drugs: semaglutide, tirzepatide, and liraglutide.
The company is currently collaborating with a pharmaceutical partner ("PharmaCO") under a material transfer agreement announced in September 2024 to evaluate DehydraTECH compositions.
Lexaria Bioscience (NASDAQ:LEXX) propone la sua tecnologia DehydraTECH come possibile soluzione alla principale sfida dell'industria GLP-1: gli effetti collaterali. Il mercato GLP-1 sta vivendo una crescita notevole, con ricavi previsti in aumento da 53,5 miliardi di dollari nel 2024 a 70,1 miliardi nel 2025, e si stima che raggiungerà 156 miliardi di dollari entro il 2030.
Tuttavia, il 47-64% degli utenti di GLP-1 interrompe il trattamento entro 1-2 anni, principalmente a causa di effetti collaterali gastrointestinali. In particolare, il 75,7% dei pazienti manifesta eventi avversi gastrointestinali con i principali farmaci GLP-1. La tecnologia DehydraTECH di Lexaria ha dimostrato in test clinici sull’uomo la capacità di ridurre gli effetti collaterali nei tre farmaci GLP-1 più utilizzati: semaglutide, tirzepatide e liraglutide.
Attualmente, l’azienda collabora con un partner farmaceutico (“PharmaCO”) nell’ambito di un accordo di trasferimento materiali annunciato a settembre 2024 per valutare le composizioni DehydraTECH.
Lexaria Bioscience (NASDAQ:LEXX) presenta su tecnología DehydraTECH como una posible solución al mayor desafío de la industria GLP-1: los efectos adversos. El mercado de GLP-1 está experimentando un crecimiento notable, con ingresos proyectados que aumentan de
Sin embargo, entre el 47% y el 64% de los usuarios de GLP-1 abandonan el tratamiento dentro de 1-2 años, principalmente debido a efectos secundarios gastrointestinales. Cabe destacar que el 75.7% de los pacientes experimentan eventos adversos gastrointestinales con los principales medicamentos GLP-1. La tecnología DehydraTECH de Lexaria ha demostrado en pruebas clínicas humanas su capacidad para reducir los efectos secundarios en los tres principales medicamentos GLP-1: semaglutida, tirzepatida y liraglutida.
La compañía está colaborando actualmente con un socio farmacéutico (“PharmaCO”) bajo un acuerdo de transferencia de materiales anunciado en septiembre de 2024 para evaluar las composiciones DehydraTECH.
Lexaria Bioscience (NASDAQ:LEXX)는 DehydraTECH 기술을 GLP-1 업계의 가장 큰 문제인 부작용 해결책으로 제시합니다. GLP-1 시장은 2024년 535억 달러에서 2025년 701억 달러로 매출이 크게 증가하고 있으며, 2030년에는 1560억 달러에 이를 것으로 예상됩니다.
그러나 GLP-1 사용자 중 47-64%가 1-2년 내 치료를 중단하는데, 주로 위장관 부작용 때문입니다. 특히, 75.7%의 환자가 주요 GLP-1 약물 복용 시 위장관 부작용을 경험합니다. Lexaria의 DehydraTECH 기술은 인간 임상시험에서 세마글루타이드, 티르제파타이드, 리라글루타이드 등 상위 3개 GLP-1 약물의 부작용을 줄이는 능력을 입증했습니다.
회사는 현재 2024년 9월 발표된 물질 이전 계약에 따라 제약 파트너("PharmaCO")와 협력하여 DehydraTECH 조성물을 평가하고 있습니다.
Lexaria Bioscience (NASDAQ:LEXX) présente sa technologie DehydraTECH comme une solution potentielle au principal défi de l'industrie GLP-1 : les effets indésirables. Le marché du GLP-1 connaît une croissance remarquable, avec des revenus projetés passant de 53,5 milliards de dollars en 2024 à 70,1 milliards en 2025, et devrait atteindre 156 milliards de dollars d'ici 2030.
Cependant, 47 à 64 % des utilisateurs de GLP-1 interrompent leur traitement dans les 1 à 2 ans, principalement en raison d'effets secondaires gastro-intestinaux. Notamment, 75,7 % des patients souffrent d'événements indésirables gastro-intestinaux avec les principaux médicaments GLP-1. La technologie DehydraTECH de Lexaria a démontré lors d'essais cliniques humains sa capacité à réduire les effets secondaires des trois principaux médicaments GLP-1 : sémaglutide, tirzépatide et liraglutide.
L'entreprise collabore actuellement avec un partenaire pharmaceutique (« PharmaCO ») dans le cadre d'un accord de transfert de matériel annoncé en septembre 2024 pour évaluer les compositions DehydraTECH.
Lexaria Bioscience (NASDAQ:LEXX) positioniert seine DehydraTECH-Technologie als potenzielle Lösung für die größte Herausforderung der GLP-1-Branche: Nebenwirkungen. Der GLP-1-Markt verzeichnet ein bemerkenswertes Wachstum, mit prognostizierten Umsätzen, die von
Allerdings brechen
Das Unternehmen arbeitet derzeit mit einem Pharma-Partner („PharmaCO“) im Rahmen einer im September 2024 angekündigten Materialtransfervereinbarung zusammen, um DehydraTECH-Zusammensetzungen zu evaluieren.
- None.
- No established commercial partnerships or licensing agreements yet announced
- Faces competition from major pharmaceutical companies in GLP-1 space
- Success depends on pharmaceutical companies adopting the technology
Insights
Lexaria's DehydraTECH shows promise reducing GLP-1 side effects, potentially addressing high discontinuation rates in this $70B+ market.
Lexaria is positioning its DehydraTECH technology as a potential solution to the most significant challenge facing the booming GLP-1 weight loss drug industry: high discontinuation rates due to gastrointestinal side effects. According to the press release, between
The market opportunity is substantial, with GLP-1 drugs generating
What makes Lexaria's approach noteworthy is that their DehydraTECH technology has reportedly demonstrated reduced side effects in human clinical testing across all three leading GLP-1 drugs currently on the market: semaglutide (Ozempic), tirzepatide (Mounjaro), and liraglutide (Victoza/Saxenda). This addresses a critical need, as exemplified by Novo Nordisk's data showing
Importantly, Lexaria has already begun commercialization efforts, having entered a material transfer agreement with an unnamed pharmaceutical company in September 2024. This suggests industry interest in their technology. The company's strategy appears focused on licensing DehydraTECH to pharmaceutical companies rather than developing their own competing GLP-1 drugs.
If DehydraTECH can meaningfully reduce dropout rates while maintaining efficacy, it could represent a valuable solution for major pharmaceutical players looking to protect and expand their GLP-1 market share in this highly competitive and rapidly growing space.
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects
DehydraTECH reduces side effects and could support patient retention and further industry growth
DehydraTECH is the only technology publicly disclosed for its ability to reduce side effects in all 3 of the top GLP-1 drugs currently sold in the world today: semaglutide, tirzepatide, and liraglutide
KELOWNA, BC / ACCESS Newswire / July 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update as the industry continues to outperform earlier revenue growth projections.
Global pharmaceutical corporations are competing desperately to secure either a foothold, or dominance, in what is currently the fastest growing pharmaceutical sector in the world: GLP-1 weight loss and diabetes control. Lexaria previously reported, on November 7, 2024, that growth expectations for the GLP-1 industry supported revenues in excess of
As time has passed, this projection now seems out-of-date and overly conservative. The latest projections are that the GLP-1 industry will be generating over
Despite remarkable revenue growth, however, there is a significant problem still plaguing the GLP-1 industry: unwanted adverse effects ("AEs") led by gastrointestinal issues, namely nausea, vomiting, diarrhea and constipation.
One study showed that between
For example, the leading GLP-1 brand in 2024 was Ozempic with
"We want to win the weight loss but we also want to have a gastrointestinal adverse event profile that is attractive and competitive," said Martin Holst Lange, EVP, Head of Development, Novo, at the Novo Nordisk R&D Investor Event hosted June 22, 2025 from the American Diabetes Association's (ADA's) 85th Scientific Sessions held in Chicago, Il. Clearly, reductions in AEs within the GLP-1 industry are highly sought after and could lead to higher patient satisfaction, lower patient dropout rates, and higher industry revenues.
Fortunately, Lexaria's patented DehydraTECH technology offers a solution. By enhancing the performance of oral dosing choices as a replacement for disliked injections, and by reducing AEs and especially gastrointestinal AEs, Lexaria's proprietary DehydraTECH technology could be of vital importance to the GLP-1 sector in the pursuit of better tolerated GLP-1 drugs.
As Lexaria has previously reported on August 28, 2024, January 14, 2025, and June 11, 2025, DehydraTECH-GLP-1 processing has repeatedly shown in human clinical testing its propensity to reduce side effects, including but not limited to gastrointestinal AEs, in all 3 of the top GLP-1 drugs currently available in the world today, being Eli Lilly and Company's® drug tirzepatide, and Novo's drugs semaglutide and liraglutide.
Lexaria is executing its multi-faceted strategy centered around its proprietary DehydraTECH processing technology. Our main goal is to attract pharmaceutical companies seeking the benefits of adopting Lexaria's DehydraTECH technology for use with their own existing drug products. This first prong of our strategy has been evidenced and validated by the Company's entry in a material transfer agreement with a pharmaceutical company ("PharmaCO") which was announced in September of 2024. Lexaria continues to collaborate with PharmaCO on evaluating DehydraTECH compositions and potential next steps.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 50 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
What is the projected market size for GLP-1 drugs by 2030 according to Lexaria (NASDAQ:LEXX)?
What percentage of GLP-1 users experience gastrointestinal side effects according to Lexaria's data?
How many patients discontinue GLP-1 treatment due to side effects?
Which major GLP-1 drugs has Lexaria's DehydraTECH technology shown effectiveness with?
What is the expected revenue growth for GLP-1 drugs from 2024 to 2025?
